Delegation of China Council for the promotion of drugs visited Germany Branch of green leaf Pharmaceutical Group (report 6 of visiting Europe)

Source: China Association for the promotion of pharmaceutical innovation on July 5, 2017, song Ruilin, executive chairman of China Association for the promotion of pharmaceutical innovation (hereinafter referred to as "China Association for the promotion of pharmaceutical") led a delegation of China Association for the promotion of pharmaceutical industry to visit the German branch of green leaf Pharmaceutical Group (green leaf Germany), vice president of green leaf Pharmaceutical Group Jiang Hua and President of green leaf Germany Jorg Scheidle, member of the board of directors of green leaf Germany, Bjorn schurad, head of development department, Monika Jung, head of registration department of green leaf Germany, Huang Wei, Deputy financial director of green leaf group, and Heike Pauly, executive assistant of green leaf Germany received the delegation Jiang Hua, vice president of green leaf group, introduced the general situation, core products, R & D strength, development strategy and successful experience of M & A of green leaf group to the delegation in detail On November 30, 2016, green leaf Pharmaceutical Group successfully acquired German acino TDS company, one of the largest independent transdermal system manufacturers in Europe, focusing on transdermal drug delivery patches Established in 1997, green leaf Pharmaceutical Group is a leading manufacturer and developer of innovative transdermal systems and implant systems Its R & D and manufacturing headquarters are in Germany and its commercial headquarters are in Switzerland The existing products include buprenorphine 3-day patch, fentanyl FNT, kabaratin, etc., which have been listed in the United States and Europe Next, they will be applied in Japan, South Korea, Brazil and other places to continue to develop the global market The successful acquisition of LVYE Germany company has greatly improved the R & D and production level of LVYE pharmaceutical in the field of new preparations; enriched the product line, improved the competition level in the core areas, improved the international level of Aluminum Group in R & D, production, international registration, market promotion and other aspects, and further developed the global market; while bringing stable business income, it has also brought Major development opportunities One belt, one road, was introduced to the green leaf Germany by the executive chairman of Song Ruilin He said that the success of the greenery group's investment in Germany coincided with the successful visit of President Xi Jinping to Germany China Council for the promotion of drugs is made up of local pharmaceutical enterprises like green leaf, which are committed to the innovation and research of drugs Green leaf group, as the vice president unit of China Association for the promotion of medicine, plays a very core and important role in the association The successful internationalization strategy of green leaf group provides a successful example for Chinese enterprises to realize the "going out" policy of relevant national industries It is hoped that green leaf can share its successful internationalization experience with the members of the association Subsequently, Jorg scheidle, chairman of LVYE Germany, accompanied the delegation to visit the transdermal preparation workshop of LVYE Germany and introduced the production process of transdermal preparation in detail The two sides discussed the technology, registration requirements and patent protection of transdermal preparations The visit to green leaf Germany took a group photo So far, the visit of the delegation of China pharmaceutical promotion association in Europe has been successfully concluded With the joint efforts of all parties, the visit has achieved great success and fruitful results The delegation held fruitful talks with international organizations and institutions such as IFPMA, who, WTO and WIPO; visited LEEM, VFA and BDI, and established good cooperative relations through exchanges; visited Sanofi (France), Bayer (Germany) and green leaf (Germany) The members of the delegation have a deeper and comprehensive understanding of the international pharmaceutical innovation policy, the current situation of European pharmaceutical industry, intellectual property protection, medical insurance reimbursement policy and international experience The whole activity has set up a higher level exchange platform for promoting the international development of Chinese pharmaceutical innovation enterprises; provided opportunities and help for Chinese pharmaceutical enterprises to go out, further strengthen international cooperation and improve the competitiveness of the international market; and laid an important foundation for the communication and exchange between China and the European and even the global pharmaceutical industry.